New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
07:03 EDTIDRAIdera Pharmaceuticals reports Q1 EPS (12c), two estimates (8c)
Reports Q1 revenue $3,000, two estimates $3,000. The company anticipates enrolling up to approximately 30 patients in a Phase 1/2 trial of IMO-8400 in patients with trial DLBCL who harbor the MYD88 L265P mutation and have relapsed or were refractory to prior therapy. The company expects to initiate patient treatment in the second half of 2014. A Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström’s macroglobulinemia, who have relapsed or were refractory to prior therapy, is ongoing. This trial is designed to evaluate safety, tolerability and clinical activity of escalating IMO-8400 dose levels. The Company anticipates enrolling up to approximately 30 patients in this trial. In March, the company announced positive top-line data from a randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. The trial met the primary objective of demonstrating safety and tolerability, as well as a secondary objective of clinical activity of IMO-8400. The company intends to submit the full data set, including data from an additional higher dose cohort, for presentation at a medical meeting in 2014.
News For IDRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
07:37 EDTIDRAStifel to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use